- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Valeant acquires rights to Targretin
Valeant Pharmaceuticals has acquired the rights to Targretin (bexarotene) gel and capsules from Eisai for $65 million.
Valeant Pharmaceuticals has acquired the rights to Targretin (bexarotene) gel and capsules from Eisai for $65 million.
The therapy is prescribed for the treatment of skin problems stemming from cutaneous T-cell lymphoma when at least one systemic therapy has been unsuccessful, according to a news release. The acquisition includes potential contingent payments based on the achievement of particular milestones.
The transaction also calls for Eisai to transfer its new drug application for Targretin to Valeant, with Valeant taking over responsibilities for regulatory obligations related to the drug in the United States. Eisai retains its rights to Targretin outside the United States.
